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Acquired Severe Aplastic Anemia
Hazzaa Al-Zahrani, Amr Nassar, Fahad Al-Mohareb, Fahad Al-Sharif, Said Mohamed,
Khalid Al-Anazi, Moosa Patel, Walid Rasheed, Abu Jafar Mohammed Saleh, Mahmoud Bakr,
Shad Ahmed, Khalid Ibrahim, Fazal Hussain, Naser Elkum, Tusneem Elhassan,
Zubeir Nurgat, Naeem Chaudhri, Mahmoud AljurfThirty-eight patients who met the diagnostic criteria for severe aplastic anemia underwent allogeneic hema-
topoietic stem cell transplantation (HSCT). The median patient age was 20 years (range, 14-36 years).
Twenty-four patients were treatment-naı¨ve, 11 had failed one or more previous courses of immunosuppres-
sive therapy, and 3 had failed a previous HSCT. The conditioning regimen included fludarabine 30 mg/m2/day
for 3 days (days29,28, and27) and cyclophosphamide 50 mg/kg/day for 4 days (days25,24,23, and22).
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short-course methotrexate.
All patients underwent transplantation with unmanipulated bone marrow as the stem cell source. The
median total nucleated cell (TNC) dose was 2.43 108/kg (range, 0.60-6.7 108/ kg). The conditioning reg-
imen was well tolerated, with minimal treatment-related mortality. Engraftment was observed in all patients
after transplantation; the median time to engraftment of neutrophils and platelets was 18 and 23 days, respec-
tively. Twenty-five of the 27 patients with available chimeric studies at day 180 maintained donor chimerism.
Acute GVHD grade$II was diagnosed in 4 patients (11%). Extensive chronic GVHD was observed in 8 pa-
tients (25%) who survived beyond day1100, at a median observation time of 43months. Graft rejection with
relapse of aplais was observed in one patient. The overall survival (OS) for the whole group was 79%. A trend
toward improved OS was observed in the treatment-naı¨ve patients (83% vs 71%), but this was statistically
insignificant (P 5 .384). The fludarabine-based conditioning regimen used in this study with relatively young
cohort of patients was well tolerated, with a low rate of rejection and treatment outcomes comparable to
those seen in other, more intense and potentially more toxic conditioning regimens. Our results await
validation in a larger study, optimally in a randomized controlled manner.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only available curative treatment for se-
vere aplastic anemia (SAA). The outcome of allogeneic
HSCT has improved significantly over the last decadedult HSCTProgram, King Faisal Specialist Hospital and
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isclosure: See Acknowledgments on page 722.
dence and reprint requests: Mahmoud Aljurf, MD,MPH,
HSCT Program, King Faisal Specialist Hospital and
rch Center, PO Box 3354, Riyadh 11211, Saudi Arabia
il: maljurf@kfshrc.edu.sa).
une 1, 2010; accepted August 16, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.08.013[1]. In patients with AA, a nonneoplastic hematologic
disorder, the main goal of transplantation is to achieve
successful engraftment, ideally without acute or
chronic graft-versus-host disease (aGVHD, cGVHD).
Despite significant progress in the structure of con-
ditioning regimens, graft failure remains a significant
concern, particularly in patients who have undergone
previous transplantation. Adequate lymphoablative
and immunoablative action of the preparative regimen
is critical in these patients [1].
Currently, a combination of antithymocyte globu-
lin (ATG) and cyclophosphamide (Cy) is considered
the standard conditioning regimen [2]. Several pro-
grams have recently used fludarabine (Flu) as the
main immunoablative/lymphoablative component,
with encouraging outcomes comparable to those
from ATG-containing conditioning but lower toxicity
[3,4].717
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experience with the use of Flu in combination with Cy
(Flu/Cy) for conditioning before HSCT in 38 consec-
utive patients with SAA. To the best of our knowledge,
this is the largest series to date examining the use of
Flu-based conditioning in prospectively and uniformly
treated SAA patients.METHODS
A total of 38 consecutive patients (all aged .14
years) with a diagnosis of SAA underwent HSCT
with grafts from fully matched sibling donors (6/6
HLA-matched siblings, as determined by low-
resolution molecular typing for the HLA-A and -B
loci and high-resolution molecular typing for the
-DR locus). Eligibility criteria included left ventricular
ejection fraction.50%, serum creatinine\130 mmol/
L, serum bilirubin \35 mmol/L, liver enzymes \2
times the upper limit of normal value, serum albumin
.30 gm/L, pulmonary function test values .50%
predicted, Karnofsky score .70%, signed informed
consent for both donor and recipient, and no contrain-
dication for bone marrow (BM) donation in the sibling
donor. Exclusion criteria included failure to meet any
of the foregoing eligibility criteria, absence of donor
or recipient consent form, human immunodeficiency
virus positivity, major psychiatric disorder, and posi-
tive pregnancy test. The hospital’s Institutional
Review Board approved the study design.Conditioning Chemotherapy and
Transplantation
All patients received Flu 30 mg/m2/day for 3 days
(days 29, 28, and 27) and Cy 50 mg/kg/day for 4
days (days25,24,23, and22). Doses were calculated
based on adjusted ideal body weight [ideal body weight
1 0.25(actual-ideal)]. GVHD prophylaxis consisted of
cyclosporine (CsA) and short-course methotrexate (15
mg/m2 on day11 and 10 mg/ m2/day on days13 and
16). Unmanipulated BMwas the stem cell source in all
grafts. Chimerism was evaluated using probes specific
for polymorphic DNA sequence short-tandem re-
peats. CsA taper was started on day 1120 using
a 10% dose reduction every 2 weeks, with the goal of
maintaining a linear taper and a careful follow-up of
blood counts with every step reduction in dose.Supportive Care
Each patient was admitted to a neutropenic isola-
tion room with HEPA filters. All patients underwent
cytomegalovirus surveillance using peripheral blood
PP65 antigenemia testing. Prophylaxis for Pneumocystis
jiroveci, herpes simplex, and Candida spp was provided
to all patients.All patients received irradiated and filtered blood
products. Red blood cell transfusions were given to
patients with a hemoglobin level\80 mg/dL. Platelet
transfusions were given to patients with a platelet
count\10  109/L, or\15  109/L in those with
fever or had clinical signs of bleeding. Febrile episodes
were treated with broad-spectrum antibiotics, which
were subsequently modified as required according to
the HSCT unit protocol. Detailed information on in-
stitutional HSCT supportive care policies and proce-
dures is provided at http://bportal.kfshrc.edu.sa/wps/
portal/bportal/KFCC.
Evaluation of Response and Definitions
Myeloid engraftment was defined as the first of 3
consecutive days with an absolute neutrophil count
(ANC).0.5 109/L. Platelet engraftment was defined
as an unsupported platelet count maintained above
20 109/L. Primary graft failure was defined as failure
to achieve an ANC .0.5  109/L for 3 consecutive
days. Secondary graft failure was defined as subsequent
development of persistent ANC \0.5  109/L after
achieving adequate engraftment, with compatible BM
hypocellularity. GVHD was graded according to the
clinical assessment using modified Seattle criteria [5].
Regimen-related toxicity was graded according to
National Cancer Institute’s CommonToxicity Criteria,
version 3 [6].
Statistical Analysis
Overall survival (OS) included all patients who
were alive at the time of last evaluation. Survival anal-
ysis was conducted using the Kaplan-Meier method;
with the log-rank test used for statistical significance
[7]. A two-sided P value\.05 was considered statisti-
cally significant. All statistical analyses were performed
using SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Between August 2004 and September 2008, a total
of 38 patients whomet the criteria of acquired SAA un-
derwent HSCT on the foregoing protocol (Table 1).
Median patient age was 20 years (range, 14-36 years).
The male:female ratio was 1.2:1, and the median
time from diagnosis to transplantation was 50 days
(range, 24-4507 days). A paroxysmal nocturnal hemo-
globinuria (PNH) clone was detected in 4 patients.
Eleven patients had failed one or more previous
courses of immunosuppressive therapy, and 3 patients
had failed a previous HSCT (2 of whom had also
received previous immunosuppressive therapy before
HSCT). The average number of blood units trans-
fused before HSCT was not accurately available,
Table 1. Patient Characteristics
Number of patients 38
Age, years, median (range) 20 (14-36)
Male: female ratio 1.2:1
Time from diagnosis to transplantation, days,
median (range)
50 (24-4507)
Failed previous immune suppression, n 11
Failed previous HSCT, n 3
Alloreactive antibodies, n 4
PNH clone, n 4
Donor–recipient sex mismatch, n 14
Donor–recipient major ABO mismatch, n 9
6/6 HLA matching, n 38
Graft TNC content,  108/kg, median (range) 2.43 (0.60-6.7)
HSCT indicates hematopoietic stem cell transplantation; PNH, paroxys-
mal nocturnal hemoglobinuria.
Table 2. Clinical Outcomes
Clinical Outcome Frequency, n (%)
Mucositis $ grade 1 29 (76)
Febrile neutropenia 36 (95)
Hepatic veno-occlusive disease (VOD) 1 (3)
Hemorrhagic cystitis 2 (5)
Hemorrhagic complications 2 (5)
Post Transplantation Lymphoproliferative Disorder 1 (3)
Acute GVHD grade $II 4 (11)
Chronic GVHD (extensive) 8 (25)
Graft rejection with aplasia (secondary) 1 (3)
PTLPD indicates posttransplantation lymphoproliferative disorders;
GVHD, graft-versus-host disease.
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Aplastic Anemiabecause most of the patients were referred from out-
side hospitals; however, 4 patients had a high titer of
alloreactive antibodies before transplantation.Total Nucleated Cell Dose, Engraftment, and
Chimerism
The median TNC dose was 2.43 108/ kg (range,
0.60-6.7  108/ kg). Engraftment was observed in all
patients after transplantation. The median time to
neutrophil engraftment was 18 days (range, 12-28
days), and that for platelet engraftment was 23 days
(range, 16-104 days).
At day1120, a donor pattern of hematopoiesis was
detected in all 32 living patients. Twenty-five of the 27
patients with available chimeric study data at day1180
still exhibited a stable or rising donor pattern. One pa-
tient experienced a total loss of donor pattern, but then
regained donor chimerism after a booster dose of stem
cells and immune suppression with mycophenolate
mofetil, and another patient with decreasing donor
pattern responded well to reinitiation of immune
suppression.Clinical Outcome
Clinical outcomes are summarized in Table 2.Toxicity
Bearman grade $I mucositis was observed in 29
patients (76%), and febrile neutropenia was seen in
36 (95%). Hepatic veno-occlusive disease (VOD) was
observed in one patient. Clinically significant hemor-
rhagic cystitis occurred in 2 patients.GVHD
aGVHD grade $II was diagnosed in 4 patients
(11%). Grade IV steroid-refractory aGVHD was the
cause of death in one patient. Extensive cGVHD was
observed in 8 (25%) of the patients who survived
beyond day 1100.Graft Rejection and Survival
At amedian observation time of of 43months post-
HSCT, only one patient (3%) demonstrated graft
rejection. This patient showed a complete loss of do-
nor chimerism with relapse of aplasia and required
an additional stem cell boost to restore donor hemato-
poiesis. Currently, he is maintaining a stable mixed
chimerism status, is off immune suppression therapy,
and is transfusion-independent.
The 43-month OS of the study population was
79% (Figure 1). When patients were stratified by pre-
vious treatment(s), the 43-month OS was 83% for the
treatment-naive group and 71% for the previously
treated group (P 5 .384) (Figure 2).
Day 1100 treatment-related mortality (TRM) was
16% (6/38 patients). Five patients suffered an early
pre-engraftment death, most due to infectious compli-
cations. One patient died because of uncontrolled
grade IV aGVHD.
Two patients died beyond day 1100 post-HSCT.
One patient died from infectious complications while
receiving immunosuppressive therapy for extensive
cGVHD, and the other died from procedure-related
hemorrhagic complications after liver biopsy.DISCUSSION
Historically, several immunoablative/lymphoabla-
tive treatments have been combined with Cy for pre-
transplantation conditioning of SAA in the setting of
a fully matched sibling donor [1,8]. Radiation therapy
in the form of total body irradiation (TBI) or total
nodal irradiation (TNI) is a potent immunoablative
therapy known to promote efficient engraftment
[1,8]. Radiation therapy in transplantation for SAA
has been associated with significant late toxicity,
however, related mainly to the development of
secondary malignancies [9].
The addition of ATG to Cy given at total dose of
200 mg/kg has been demonstrated to promote excel-
lent engraftment and long-term outcome. Presently,
this combination is considered more or less the
Figure 1. Kaplan-Meier OS curve for all patients.
Figure 2. Kaplan-Meier OS survival curves according to previous
treatment.
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of matched related HSCT [2]. However, ATG is asso-
ciated with significant side effects including, but not
limited to, immediate allergic reaction, hemolysis, in-
creased risk of infection, serum sickness–like reaction,
and even secondary renal dysfunction. ATG toxicity
also tends to be more pronounced with age. Moreover,
the prohibitive cost of ATG therapymakes it unafford-
able in many transplant centers, particularly in some
developing countries where SAA may occur at higher
frequencies [10].
Prevention of graft failure can be addressed with
other, more intense conventional conditioning regi-
mens. However, this benefit can be offset by higher
treatment-related morbidity and TRM in a disease for
which the primary goal of transplantation is only to se-
cure adequate and durable engraftment and there is no
malignancy requiring eradication by high-dose chemo-
radiotherapy or a graft-versus-malignancy effect [1].
Flu is a purine analog with potent lymphoablative
and immunoablative effects. It works synergistically
with cyclophosphamide by inhibiting alkylation-
induced DNA repair [11]. Flu is known to induce
protracted lymphopenia with significant depression of
CD4 and CD8 lymphocytes and occasional develop-
ment of transfusion-associatedGVHDwhen nonirradi-
ated blood products are administered [11]. Compared
with ATG and TBI, it is well tolerated, with minimal
short- and long-term side effects [11].
The use of Flu as an engraftment-promoting im-
munoablative/lymphoablative conditioning compo-
nent is increasing because of the drug’s wide
availability, high tolerability even at older ages, and af-
fordability. Flu is particularly useful when an effective
immunoablative and lymphoablative component is
needed, such as in reduced-intensity conditioning
(RIC) and in patients with a nonneoplastic hemato-
logic disorder who are heavily pretransfused, such as
those with acquired AA, other BM failure syndromes,and hemoglobinopathies [3,4]. The Flu-based condi-
tioning regimen used in the present study was well
tolerated, with very limited toxicity.
Unmanipulated BM provided the stem cell source
for all patients, based on retrospective data from the
International Bone Marrow Transplant Registry and
the European Group for Blood and Marrow Trans-
plantation (EBMT) suggesting inferior outcomes
with the use of peripheral blood stem cells (PBSCs)
in this disease. In addition, the current consensus of
the EBMT’s Severe Aplastic Anemia Working Party
recommends using BM as the stem cell source in the
matched related transplantation setting [1].
Overall transplantation complications and mor-
bidity in this study were acceptable, with no unusual
complications or toxicities observed. Of note, our
subjects were of younger median age than the AA
patients reported in previous studies from Western
Europe and North America, which possibly could
have contributed to a more favorable outcome.
On the other hand, although data on pretransplan-
tation transfusions were not available for our study
patients, the median time from diagnosis to transplan-
tation in our study is much longer than that in the
studies fromWestern Europe and North America. In-
tuitively, reducing and possibly almost eliminating
pretransplantation transfusions would markedly
improve patient outcomes. Moreover, the long delay
with cytopenia before transplantation could have con-
tributed to an increased susceptibility to infection and
the increased number of sepsis-related deaths in our
patients.
The number of patients who developed aGVHD
or cGVHDwas limited, and the incidence was compa-
rable to that reported in previous studies, including
Table 3. Reports on Fludarabine-Based Conditioning with Different Outcomes
Present Study Mahmoud et al. [13] Kumar et al. [14] Ambulkar et al. [15] Go´mez-Almaguer [16] Resnick et al. [4] Srinivasan et al. [17]
Age, years, median (range) 20 (14-36) 18 (17-36) 25 (4-65) 20 (9-55) 30 (11-65)
Number of patients 38 17 5 24 23 13 26
Flu, mg/m2 30/day  3 30/day  3 30/day  6 30/day  6 30/day  3 30/day  6 25/day  5
Cy, mg/m2 1000/day  2 350/day  3
Cy, mg/kg 50/day  4 60/day  2 60/day  2 60/day  2 60/day  2
Others ATG 30-40/kg/day  4 days Bu ATG 10/kg/day  4 days ATG 40/kg/day  4 days
4 mg/kg/day  2
Acute GVHD, % 11 23.5 20 29 17.3 grade I-II 8.3 65
Chronic GVHD, % 25 0 40 32 26 12.5 56
OS, % 79 88.2 100 82.8 88 at 1500 days 84 at 5 years 77
Type Matched sibling Matched sibling Matched sibling Matched sibling Matched related Matched related 5 22; one
antigen mismatch 5 4
Source Unmanipulated BM Unmanipulated PBSCs Unmanipulated PBSCs Unmanipulated PBSCs PBSCs 5 9; BM 5 4 Unmanipulated PBSCs
George et al. [3] Kang et al. [18] Gupta et al. [19] Bacigalupo et al. [20] Chan et al. [21]
Age, years, median (range) 20.8 (5-43) 7-18 13(8-35) 14 (3-37) 0.7-11.5
Number of patients 35 5 7 38 5
Flu, mg/m2 30/day  6 30/day  4 30/day  4-5 30/day  4 30/day  4-5
Cy, mg/m2 300/day  4 300/day  4
Cy, mg/kg 60/day  2 50/day  4 60/day  2 or 50 mg/kg  4
Other ATG 10/kg/day 4 (n5 11) ATG 2.5/kg/day  3 Pediatric: Campath 0-2/kg/
day  5
ATG 3.75 mg/kg  4 ATG 30 mg/kg  4
Adult: Campath 20/day  5
Acute GVHD, % 29 20 42.8 11 40
Chronic GVHD, % 32 0 16.6 27 80
OS, % 82.8 at 22 months 80 at 566 days 71.4 73 at 2 years 100
Type Matched related Matched unrelated Matched unrelated Matched unrelated 5 33,
related mismatched 5 5
Related one locus
mismatched 5 3;
matched unrelated 5 2
Source Granulocyte colony-
stimulating factor PBSCs
5 28; BM 5 7
Unmanipulated BM Unmanipulated BM Unmanipulated BM 5 36;
unmanipulated PBSCs 5
2
Unmanipulated BM
ATG indicates antithymocyte globulin; BM, bone marrow; Bu, busulfan; PBSC, peripheral blood stem cell; Flu, fludarabine; Cy, cyclophosphamide; GVHD, graft-versus-host disease; OS, overall survival.
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722 Biol Blood Marrow Transplant 17:717-722, 2011H. Al-Zahrani et al.studies that used Cy and ATG for conditioning. We
have previously reported on the lower likelihood of
GVHD in our region of the world, presumably related
to the high racial and genetic homogeneity of our pop-
ulation. The possibility that this factor contributed to
the limited GVHD observed in the present study
cannot be excluded [12].
Engraftment rates were satisfactory even for those
patients who had failed previous immunosuppressive
therapy or HSCT. Such patients have been consis-
tently reported to be at high risk for graft failure in
previous studies.
Numerous reports from single-institution studies
have described the use of Flu-based conditioning in
different schedules and combinations for HSCT for
aplastic anemia with favorable outcomes [3,4,13-21]
(Table 3). Retrospective data from an EBMT study
also suggested favorable outcomes with the use of
Flu-based conditioning for HSCT for AA in older
patients [22].
Our institution is a tertiary care referral institution
for HSCT and BM failure disorders in particular and
we cannot exclude the possibility of some selection
bias based on patient referral. Obviously, our finding
of favorable outcomes from a Flu-based conditioning
regimen for HSCT to treat SAA in a relatively young
cohort of patients, as well as the findings of other
single-center studies, await validation in a larger study,
ideally in a randomized controlled manner.ACKNOWLEDGMENTS
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